Induction of coagulation effects by Wyeth-14,643 in Crl:CD BR rats.
A two-year mechanistic bioassay in male Crl:CD BR rats was initiated with 50 ppm Wyeth-14,643 (WY) to investigate the relationship between peroxisome proliferating compounds and Leydig cell adenoma formation. After 154 days, the survival rate in the WY group decreased below control levels. After 300 days, the dose was lowered to 25 ppm for the remainder of the study. Gross examination of WY-treated rats either found dead or euthanized in extremis revealed hemorrhages at several sites. To investigate this observation, blood was then collected on test day 281 from 10 randomly selected control and WY-treated rats and a clinical pathological examination was performed. The WY-treated rats had significantly decreased red blood cell count, hemoglobin, and hematocrit, and elevated platelet counts. In the WY-treated rats, prothrombin times in undiluted plasma were similar to the controls, but were markedly prolonged in 2 of 10 rats when the plasma samples were diluted to 25%. Subsequently, blood was collected prior to sacrificing WY-treated rats which were exhibiting clinical signs of anemia. These rats had prolonged prothrombin times, activated partial thromboplastin time, and thrombin clot time when compared to laboratory historical control data (116.7 vs 13.3, 116.4 vs 13.7, and 42.4 vs 25.7 seconds, respectively). In a subsequent, ongoing study, Vitamin K was added to control and WY-treated diets (100 ppm). No survival differences between control and WY-treated rats occurred through 260 days in this second study. These new data suggest that deaths in the WY-treated group in our initial study were due to a vitamin K deficiency. The role of increased serum estradiol, its effects on blood coagulation, and enhanced hepatic cell proliferation in the vitamin K-dependent coagulation processes warrant further investigation.
Hurtt
M E
ME
Haskell Laboratory for Toxicology and Industrial Medicine, E. I. du Pont de Nemours and Company, Newark, Delaware 19714, USA.
Elliott
G S
GS
Cook
J C
JC
Obourn
J D
JD
Frame
S R
SR
Biegel
L B
LB
D000704:Analysis of Variance; D000818:Animals; D001681:Biological Assay; D001777:Blood Coagulation / Q000187:drug effects*; D001800:Blood Specimen Collection; D002273:Carcinogens / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D004906:Erythrocyte Count / Q000187:drug effects; D006400:Hematocrit; D006454:Hemoglobins / Q000378:metabolism; D007984:Leydig Cell Tumor / Q000097:blood / Q000139:chemically induced* / Q000401:mortality; D008297:Male; D008830:Microbodies / Q000187:drug effects; D009153:Mutagens / Q000633:toxicity*; D010314:Partial Thromboplastin Time; D010976:Platelet Count / Q000187:drug effects; D011517:Prothrombin Time; D011743:Pyrimidines / Q000008:administration & dosage / Q000633:toxicity*; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D015996:Survival Rate; D013736:Testicular Neoplasms / Q000097:blood / Q000139:chemically induced* / Q000401:mortality; D013917:Thrombin / Q000378:metabolism; D014813:Vitamin K Deficiency / Q000097:blood / Q000139:chemically induced / Q000401:mortality
D002273:Carcinogens; D006454:Hemoglobins; D009153:Mutagens; D011743:Pyrimidines; C006253:pirinixic acid; D013917:Thrombin